BridgeBio Pharma, Inc. Stock price

Equities

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
30.92 USD +0.19% Intraday chart for BridgeBio Pharma, Inc. +6.69% -23.41%
Sales 2024 * 132M Sales 2025 * 217M Capitalization 5.7B
Net income 2024 * -623M Net income 2025 * -589M EV / Sales 2024 * 54.1 x
Net Debt 2024 * 1.42B Net Debt 2025 * 1.25B EV / Sales 2025 * 32.1 x
P/E ratio 2024 *
-9.31 x
P/E ratio 2025 *
-9.84 x
Employees 553
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.19%
1 week+6.69%
Current month-9.46%
1 month-12.38%
3 months-26.05%
6 months+13.97%
Current year-23.41%
More quotes
1 week
28.91
Extreme 28.91
31.23
1 month
26.82
Extreme 26.82
36.41
Current year
26.82
Extreme 26.82
41.04
1 year
12.75
Extreme 12.75
44.32
3 years
4.98
Extreme 4.98
65.33
5 years
4.98
Extreme 4.98
73.50
10 years
4.98
Extreme 4.98
73.50
More quotes
Managers TitleAgeSince
Founder 45 14-12-31
Founder 75 14-12-31
Founder 73 14-12-31
Members of the board TitleAgeSince
Director/Board Member 52 16-02-29
Founder 73 14-12-31
Director/Board Member 78 21-08-16
More insiders
Date Price Change Volume
24-03-28 30.92 +0.19% 2,004,455
24-03-27 30.86 +3.70% 1,785,083
24-03-26 29.76 +1.26% 1,956,297
24-03-25 29.39 -0.64% 765,773
24-03-22 29.58 +2.07% 1,569,061

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
30.92 USD
Average target price
49.38 USD
Spread / Average Target
+59.72%
Consensus
  1. Stock
  2. Equities
  3. Stock BridgeBio Pharma, Inc. - Nasdaq